Skip to main content
Log in

Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavours, with low response rates and survival rarely exceeding 6 months. There are no standard chemotherapeutic regimens and new therapeutic approaches have to be found. We report an open-label, uncontrolled, multicentre phase II trial of lonidamine (LND) and diazepam in 16 patients with GBM at first relapse and a Karnofsky performance status ≥70. The treatment regimen consisted of LND 450 mg/day and diazepam 15 mg/day orally of every 28-day cycle until progression or unacceptable toxicity. Patients received a median of three cycles (range, 1–12). No complete or partial response was observed. Therefore, according to the design of the study, no additional patients were enrolled and the trial was closed. Nevertheless, seven stabilizations (50%) were observed. Median time to progression was 8 weeks (range, 5–19 weeks). Median overall survival from recurrence was 15 weeks (range, 14–61 weeks). No grade 3–4 toxicity, except somnolence, was observed and there were no therapy-related deaths. Dose reduction for diazepam due to somnolence (grade III) was performed in 9 patients. The combination of LND and diazepam is well tolerated. LND and diazepam, acting on two distinct mitochondrial sites involved in cellular energy metabolism, may exert a cytostatic effect on tumour growth as shown by the high percentage of stable patients. The LND–diazepam at the used dosing schedule did not show a complete or partial response. LND plus diazepam may be interesting in the adjuvant setting or associated to chemotherapy to act on different targets and increase the therapeutic index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Delattre JY, Uchuya M: Radiotherapy and chemotherapy for gliomas. Curr Opin Oncol 8: 196-203, 1996

    Google Scholar 

  2. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956

    Google Scholar 

  3. Nakashima RA, Mangan PS, Colombini M, Pedersen PL: Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N?-dicyclohexylcarbodiimide-labelling studies for the involvement of the pore-forming protein VDAC. Biochemistry 25: 1015-1021, 1986

    Google Scholar 

  4. Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, Poisson M, Dutrillaux B, Poupon MF: High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 74: 839-845, 1996

    Google Scholar 

  5. Bigner SH, Mark J, Bigner DD: Cytogenetics of human brain tumours. Cancer Genet Cytogenet 47: 141-154, 1990

    Google Scholar 

  6. Linden M, Gellerfors P, Nelson BD: Pore protein and the hexokinase-binding protein from the outer membrane of rat liver mitochondria are identical. FEBS Lett 14: 189-192, 1982

    Google Scholar 

  7. Miettinen H, Kononen J, Haapasalo H, Helen P, Sallinen P, Harjuntausta T, Helin H, Alho H: Expression of peripheral-type benzodiazepine receptor and diazepambinding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 55: 2691-2695, 1995

    Google Scholar 

  8. Wang JKT, Morgan JI, Spector S: Differentiation of Friend erythroleukemia cells induced by benzodiazepines.Proc Natl Acad Sci USA 81: 3770-3772, 1984

    Google Scholar 

  9. Wang JKT, Morgan JI, Spector S: Benzodiazepines that bind at peripheral sites inhibits cell proliferation. Proc Natl Acad Sci USA 81: 753-756, 1984

    Google Scholar 

  10. Carayon P, Portier M, Dussossoy D, Bord A, Petitpretre G, Canat X, Le Fur G, Casellas P: Involvement of peripheral benzodiazepine receptors in the protection of haematopoietic cells against oxygen radical damage. Blood 87: 3170-3178, 1996

    Google Scholar 

  11. Miccoli L, Poirson-Bichat F, Sureau F, Bras Goncalves R, Bourgeois Y, Dutrillaux B, Poupon MF, Oudard S: Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 18: 1400-1406, 1998

    Google Scholar 

  12. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumour cells. Cancer Res 41: 4661-4666, 1981

    Google Scholar 

  13. Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B, Poupon MF: Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62: 216-222, 1995

    Google Scholar 

  14. Carapella CM, Paggi MG, Cattani F, Ciottoli GB, Floridi A, Iandolo B, Raus L, Riccio A, Caputo A: The potential role of lonidamine in the treatment of malignant gliomas; a phase II study. J Neuro-Oncol 7: 103-108, 1989

    Google Scholar 

  15. Braestrup C, Squires RF: Specific benzodiazepine receptors in rat brain characterized by high-affinity [3H]diazepam binding. Proc Natl Acad Sci USA 74: 3805-3809, 1997

    Google Scholar 

  16. Floridi A, Lehninger AL: Action of the antitumour and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys 226: 73-83, 1983

    Google Scholar 

  17. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G: Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18: 2537-2546, 1999

    Google Scholar 

  18. Beurdeley-Thomas A, Miccoli L, Oudard S, Dutrillaux B, Poupon MF: The peripheral benzodiazepine receptors: a review. J Neuro-Oncol 46: 45-56, 2000

    Google Scholar 

  19. Carapella CM, Paggi MG, Calvosa F, Cattani F, Jandolo B, Mastrostefano R, Raus L, Riccio A: Lonidamine in the combined treatment of malignant gliomas. J Neurosurg Sci 34: 261-264, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oudard, S., Carpentier, A., Banu, E. et al. Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme. J Neurooncol 63, 81–86 (2003). https://doi.org/10.1023/A:1023756707900

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023756707900

Navigation